Melpignano M, Vadora E, Debiasi D, Merisio C, Piombo S, Brusati M, Catozzi L, Giovannini G, Piffanelli A, Merialdi A
Department of Obstetrics and Gynecology, University of Parma, Italy.
Acta Biomed Ateneo Parmense. 1993;64(5-6):227-34.
In 62 cases of gynecological malignancies, 16 of the ovarian, 31 of the endometrium and 15 of the cervix, the EGF-R status was evaluated in order to establish its prognostic value and its correlation with other classical prognostic factors. We have failed to demonstrate any correlation between EGF-R status and stage, grade and hormonal receptors, ER/PgR, in ovarian and cervical cancer. In contrast, in endometrial cancer, we observed significantly lower levels of EGF-R in poorly differentiated tumors. Moreover, a weak negative relationship between EGF-R and PgR status was found. Regarding survival, we noticed a better prognosis in patients with ovarian cancer EGF-R positive, but without statistical significance.
在62例妇科恶性肿瘤患者中,其中卵巢癌16例、子宫内膜癌31例、宫颈癌15例,对其表皮生长因子受体(EGF-R)状态进行评估,以确定其预后价值及其与其他经典预后因素的相关性。我们未能证明卵巢癌和宫颈癌中EGF-R状态与分期、分级及激素受体(ER/PgR)之间存在任何相关性。相比之下,在子宫内膜癌中,我们观察到低分化肿瘤的EGF-R水平明显较低。此外,还发现EGF-R与PgR状态之间存在微弱的负相关关系。关于生存率,我们注意到EGF-R阳性的卵巢癌患者预后较好,但无统计学意义。